Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
GenFleet Therapeutics
company
About
GenFleet Therapeutics is a biotechnology developer and researcher of molecular pharmaceuticals targeting cancer treatments.
- 11 - 50
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- ¥500M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2017
- Number Of Employee
- 11 - 50
- Operating Status
- Active
GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize the body's own immune system.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
¥500M
GenFleet Therapeutics has raised a total of
¥500M
in funding over 2 rounds. Their latest funding was raised on
Dec 31, 2021 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 31, 2021 | Series C | ¥500M | 3 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
3
GenFleet Therapeutics is funded by 3 investors.
Qiaojing Eastern Investment
and Wenzhou Dongchuang Xinhui
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
|
|
— | Series C |
Shanjin Capital
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
